Literature DB >> 33367696

Individual and healthcare supply-related barriers to treatment initiation in HIV-positive patients enrolled in the Cameroonian antiretroviral treatment access programme.

Pierre-Julien Coulaud1, Camélia Protopopescu1, Khadim Ndiaye1, Maël Baudoin1, Gwenaëlle Maradan1,2, Christian Laurent3, Bruno Spire1, Laurent Vidal1, Christopher Kuaban4, Sylvie Boyer1.   

Abstract

Increasing demand for antiretroviral treatment (ART) together with a reduction in international funding during the last decade may jeopardize access to ART. Using data from a cross-sectional survey conducted in 2014 in 19 HIV services in the Centre and Littoral regions in Cameroon, we investigated the role of healthcare supply-related factors in time to ART initiation in HIV-positive patients eligible for ART at HIV diagnosis. HIV service profiles were built using cluster analysis. Factors associated with time to ART initiation were identified using a multilevel Cox model. The study population included 847 HIV-positive patients (women 72%, median age: 39 years). Median (interquartile range) time to ART initiation was 1.6 (0.5-4.3) months. Four HIV service profiles were identified: (1) small services with a limited staff practising partial task-shifting (n = 4); (2) experienced and well-equipped services practising task-shifting and involving HIV community-based organizations (n = 5); (3) small services with limited resources and activities (n = 6); (4) small services providing a large range of activities using task-shifting and involving HIV community-based organizations (n = 4). The multivariable model showed that HIV-positive patients over 39 years old [hazard ratio: 1.26 (95% confidence interval) (1.09-1.45), P = 0.002], those with disease symptoms [1.21 (1.04-1.41), P = 0.015] and those with hepatitis B co-infection [2.31 (1.15-4.66), P = 0.019] were all more likely to initiate ART early. However, patients in the first profile were less likely to initiate ART early [0.80 (0.65-0.99), P = 0.049] than those in the second profile, as were patients in the third profile [association only significant at the 10% level; 0.86 (0.72-1.02), P = 0.090]. Our findings provide a better understanding of the role played by healthcare supply-related factors in ART initiation. In HIV services with limited capacity, task-shifting and support from community-based organizations may improve treatment access. Additional funding is required to relieve healthcare supply-related barriers and achieve the goal of universal ART access.
© The Author(s) 2020. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cameroon; HIV; healthcare supply-related factors; time to ART initiation

Mesh:

Substances:

Year:  2021        PMID: 33367696     DOI: 10.1093/heapol/czaa153

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  2 in total

1.  Individual and healthcare supply-related HIV transmission factors in HIV-positive patients enrolled in the antiretroviral treatment access program in the Centre and Littoral regions in Cameroon (ANRS-12288 EVOLCam survey).

Authors:  Pierre-Julien Coulaud; Abdourahmane Sow; Luis Sagaon-Teyssier; Khadim Ndiaye; Gwenaëlle Maradan; Christian Laurent; Bruno Spire; Laurent Vidal; Christopher Kuaban; Sylvie Boyer
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.240

2.  Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).

Authors:  Marion Mora; Giovanna Rincon; Michel Bourrelly; Gwenaëlle Maradan; Anaenza Freire Maresca; Florence Michard; Elisabeth Rouveix; Julie Pannetier; Diane Leriche; Tristan Alain; Yazdan Yazdanpanah; David Michels; Bruno Spire
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.